First Choice Neurology Research Center 1 Clinical Trials
First Choice Neurology Research Centers offer clinical trials for Alzheimer’s disease (AD), Dementia, Tonic Clonic Seizures, and other neurological disorders.
Research Center 1 Clinical Trials
AZT-001 by AZTherapies, Inc.
This is a global 72-week study for subjects with evidence of early AD. The protocol is designed to determine whether ALZT-OP1 combination treatment (ALZT-OP1a + ALZT-OP1b) will slow down, arrests, or reverse cognitive and functional decline, in subjects with evidence of early-stage Alzheimer’s disease (AD). Patients must be between 55 and 79 years of age. Informant/study partner needed (compensation provided).
Longeveron (Allogenic Human Mesenchymal Stem Cells)
Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSC) Infusion Versus Placebo in Patients with Alzheimer’s Disease. This is a 52-week phase I study for patients with early Alzheimer’s MMSE 18-24. Patients must be between 50 and 80 years of age. Informant/study partner needed (compensation provided).
YKP3089C025 by SK Life Science, Inc.
Placebo-controlled 34-week clinical trial for patients with Primary Generalized Tonic Clonic Seizures to evaluate the safety and efficacy of Cenobamate as an adjunctive therapy.
TRIAD by Avanir
This is a 12-week clinical trial, investigating d6-DM/Q for the treatment of agitation in patients with dementia of the Alzheimer’s type. Patients must be between 50 and 90 years of age and have a MMSE score of 6 to 26. Informant/study partner needed (compensation provided).
Contact First Choice Neurology Research Center 1
The Neurology Group, LLC
9090 SW 87 Court, Suite 200
Miami, FL 33176
Phone: (305) 596-2080
Fax: (305) 351-7905
(305) 596-2080 ext. 1112